Efficacy and Safety of Endovascular Treatment versus Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials
Background and Purpose Although endovascular therapy (ET) is increasingly used in patients with moderate to severe acute ischemic stroke, its efficacy and safety remains controversial. We performed a meta-analysis aiming to compare the benefits and safety of endovascular treatment and intravenous thrombolysis in the treatment of acute ischemic stroke. Methods We systematically searched PubMed, Embase, Science direct and Springer unitil July, 2013. The primary outcomes included good outcome (mRS ≤ 2) and excellent outcome (mRS ≤ 1) at 90 days or at trial end point. Secondary outcomes were occurrence of symptomatic hemorrhage and all-cause mortality. Results Using a prespecified search strategy, 5 RCTs with 1106 patients comparing ET and intravenous thrombolysis (IVT) were included in the meta-analysis. ET and IVT were associated with similar good (43.06% vs 41.78%; OR=1.14; 95% CI, 0.77 to 1.69; P=0.52;) and excellent (30.43% vs 30.42%; OR=1.05; 95% CI, 0.80 to 1.38; P=0.72;) outcome. For additional end points, ET was not associated with increased occurrence of symptomatic hemorrhage (6.25% vs. 6.22%; OR=1.03; 95% CI, 0.62 to 1.69; P=0.91;), or all-cause mortality (18.45% vs. 17.35%; OR=1.00; 95% CI, 0.73 to 1.39; P=0.99;). Conclusions Formal meta-analysis indicates that there are similar safety outcomes and functional independence with endovascular therapy and intravenous thrombolysis for acute ischemic stroke.
References
[1]
Johnston SC, Mendis S, Mathers CD (2009) Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol 8: 345-354. doi:10.1016/S1474-4422(09)70023-7. PubMed: 19233730.
[2]
Kung HC, Hoyert DL, Xu J, Murphy SL (2008) Deaths: final data for 2005. Natl Vital Stat Rep 56: 1-120. PubMed: 18512336.
[3]
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S et al. (2010) Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 121: 215-46e10.1161/CIRCULATIONAHA.109.192667. PubMed: 20019324.
[4]
Wardlaw JM, Murray V, Berge E, del ZG, Sandercock P et al. (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379: 2364-2372. doi:10.1016/S0140-6736(12)60738-7. PubMed: 22632907.
[5]
(1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581-1587. doi:10.1056/NEJM199512143332401. PubMed: 7477192.
[6]
Lees KR, Bluhmki E, von KR, Brott TG, Toni D et al. (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375: 1695-1703. doi:10.1016/S0140-6736(10)60491-6. PubMed: 20472172.
[7]
Furlan A, Higashida R, Wechsler L, Gent M, Rowley H et al. (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282: 2003-2011. doi:10.1001/jama.282.21.2003. PubMed: 10591382.
[8]
Lee M, Hong KS, Saver JL (2010) Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 41: 932-937. doi:10.1161/STROKEAHA.109.574335. PubMed: 20360549.
[9]
Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P et al. (2013) Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368: 893-903. doi:10.1056/NEJMoa1214300. PubMed: 23390923.
[10]
Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M et al. (2013) Endovascular treatment for acute ischemic stroke. N Engl J Med 368: 904-913. doi:10.1056/NEJMoa1213701. PubMed: 23387822.
[11]
Zhang B, Sun X, Li M, Wang F, Xu D et al. (2010) Intra-arterial vs intra-venous. Thrombolysis for anterior cerebral occlusion. Can J Neurol Sci 37: 240-244. PubMed: 20437936.
[12]
Sugiura S, Iwaisako K, Toyota S, Takimoto H (2008) Simultaneous treatment with intravenous recombinant tissue plasminogen activator and endovascular therapy for acute ischemic stroke within 3 hours of onset. AJNR Am J Neuroradiol 29: 1061-1066. doi:10.3174/ajnr.A1012. PubMed: 18372418.
[13]
Nam J, Jing H, O'Reilly D (2013) Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysis. Int J Stroke. doi:10.1111/j.1747-4949.2012.00914.x.
[14]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17: 1-12. doi:10.1016/S0197-2456(96)90740-0. PubMed: 8721797.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6: e1000097.
[17]
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med 6: e1000100. PubMed: 196315071962251219621070.
[18]
Ducrocq X, Bracard S, Taillandier L, Anxionnat R, Lacour JC et al. (2005) Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke. J Neuroradiol 32: 26-32. doi:10.1016/S0150-9861(05)83018-4. PubMed: 15798610.
[19]
Ciccone A, Valvassori L, Ponzio M, Ballabio E, Gasparotti R et al. (2010) Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg 2: 74-79. doi:10.1136/jnis.2009.001388. PubMed: 21990564.
[20]
Sen S, Huang DY, Akhavan O, Wilson S, Verro P et al. (2009) IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study. Neurocrit Care 11: 76-81. doi:10.1007/s12028-009-9204-1. PubMed: 19277904.
[21]
Adams HP Jr, del ZG, Alberts MJ, Bhatt DL, Brass L et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655-1711. doi:10.1161/STROKEAHA.107.181486. PubMed: 17431204.
[22]
Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN et al. (2012) Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e601S-e636S. doi:10.1378/chest.11-2302. PubMed: 22315273.
[23]
Hussein HM, Georgiadis AL, Vazquez G, Miley JT, Memon MZ et al. (2010) Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. AJNR Am J Neuroradiol 31: 454-458. doi:10.3174/ajnr.A2006. PubMed: 20075087.
[24]
Rha JH, Saver JL (2007) The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38: 967-973. doi:10.1161/01.STR.0000258112.14918.24. PubMed: 17272772.
[25]
Kidwell CS, Alger JR, Saver JL (2003) Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34: 2729-2735. doi:10.1161/01.STR.0000097608.38779.CC. PubMed: 14576370.
[26]
Boersma E (2006) Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27: 779-788. doi:10.1093/eurheartj/ehi810. PubMed: 16513663.
[27]
De Luca G, Cassetti E, Marino P (2009) Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 27: 712-719. doi:10.1016/j.ajem.2008.04.026. PubMed: 19751630.
[28]
Molina CA, Alvarez-Sabín J, Montaner J, Abilleira S, Arenillas JF et al. (2002) Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 33: 1551-1556. doi:10.1161/01.STR.0000016323.13456.E5. PubMed: 12052990.
[29]
Berger C, Fiorelli M, Steiner T, Sch？bitz WR, Bozzao L et al. (2001) Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic. Stroke 32: 1330-1335. doi:10.1161/01.STR.32.6.1330. PubMed: 11387495.
[30]
Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B et al. (2012) Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 380: 1241-1249. doi:10.1016/S0140-6736(12)61384-1. PubMed: 22932715.
[31]
Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW et al. (2012) Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 380: 1231-1240. doi:10.1016/S0140-6736(12)61299-9. PubMed: 22932714.
